- Bolt Biotherapeutics Inc (NASDAQ:BOLT) reported topline data from the dose-escalation study of BDC-1001 in HER2-expressing solid tumors that support advancing into two Phase 2 studies.
- BDC-1001 was well tolerated at all dose levels and schedules evaluated, both as monotherapy and combined with Bristol Myers Squibb & Co (NYSE:BMY) Opdivo (nivolumab).
- Target drug exposure levels were achieved at or near the recommended Phase 2 dose (RP2D) by more frequent administration, including every other week (q2w) and weekly (q1w) administration schedules.
- Anti-tumor activity was observed in the form of multiple partial responses (PRs), tumor shrinkage, and long-term stable disease at or near the RP2D across multiple HER2-expressing solid tumor types in monotherapy and combination with nivolumab.
- Moreover, biomarker data demonstrate that corresponding clinical and safety data are related to the ISAC mechanism.
- Bolt Biotherapeutics also entered into a clinical supply agreement with Roche Holdings AG (OTC: RHHBY) to evaluate pertuzumab (Perjeta) in combination with BDC-1001.
- Price Action: BOLT shares are down 2.33% at $1.26 on the last check Thursday.
‘Twitter Considers Charging Brands $1000/Month To Stay Verified’ – TheInformation
https://www.theinformation.com/briefings/twitter-considers-charging-brands-1000-per-month-to-stay-verified
